{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T20:46:15Z","timestamp":1792356375341,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41409-019-0582-5","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T12:02:24Z","timestamp":1559304144000},"page":"1987-1994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT"],"prefix":"10.1038","volume":"54","author":[{"given":"Annalisa","family":"Ruggeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Paviglianiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Volt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bacigalupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yener","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2767-8191","authenticated-orcid":false,"given":"Guillermo","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6006-8088","authenticated-orcid":false,"given":"Erick","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Gluckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"key":"582_CR1","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt \u00d8stg\u00e5rd","year":"2015","unstructured":"Granfeldt \u00d8stg\u00e5rd LS, Medeiros BC, Sengel\u00f8v H, N\u00f8rgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a National Population-Based Cohort Study. J Clin Oncol. 2015;33:3641\u20139.","journal-title":"J Clin Oncol"},{"key":"582_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"582_CR3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367\u201376.","journal-title":"Blood"},{"key":"582_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518:552\u20135.","journal-title":"Nature"},{"key":"582_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ajh.23605","volume":"89","author":"MC Ornstein","year":"2014","unstructured":"Ornstein MC, Mukherjee S, Mohan S, Elson P, Tiu RV, Saunthararajah Y, et al. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia. Am J Hematol. 2014;89:168\u201373.","journal-title":"Am J Hematol"},{"key":"582_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5045\/br.2013.48.3.185","volume":"48","author":"SH Park","year":"2013","unstructured":"Park SH, Chi H-S, Cho Y-U, Jang S, Park C-J. Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia. Blood Res. 2013;48:185\u201392.","journal-title":"Blood Res"},{"key":"582_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.leukres.2013.04.016","volume":"37","author":"MG Della Porta","year":"2013","unstructured":"Della Porta MG. Prognosis of secondary acute myeloid leukemia. Leuk Res. 2013;37:857\u20138.","journal-title":"Leuk Res"},{"key":"582_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/bbmt.2002.v8.pm12064362","volume":"8","author":"JN Barker","year":"2002","unstructured":"Barker JN, Krepski TP, DeFor TE, Davies SM, Wagner JE, Weisdorf DJ. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant. 2002;8:257\u201360.","journal-title":"Biol Blood Marrow Transplant"},{"key":"582_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3324\/haematol.2015.141119","volume":"101","author":"J-M Tiercy","year":"2016","unstructured":"Tiercy J-M. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica. 2016;101:680\u20137.","journal-title":"Haematologica"},{"key":"582_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.2016.151779","volume":"102","author":"A Ruggeri","year":"2017","unstructured":"Ruggeri A, Sun Y, Labopin M, Bacigalupo A, Lorentino F, Arcese W, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. Haematologica. 2017;102:401\u201310.","journal-title":"Haematologica"},{"key":"582_CR11","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/s41409-018-0153-1","volume":"53","author":"JR Passweg","year":"2018","unstructured":"Passweg JR, Baldomero H, Bader P, Basak GW, Bonini C, Duarte R, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2018;53:1139\u201348.","journal-title":"Bone Marrow Transplant"},{"key":"582_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.bbmt.2014.11.675","volume":"21","author":"M Robin","year":"2015","unstructured":"Robin M, Ruggeri A, Labopin M, Niederwieser D, Tabrizi R, Sanz G, et al. Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. Biol Blood Marrow Transpl. 2015;21:489\u201395.","journal-title":"Biol Blood Marrow Transpl"},{"key":"582_CR13","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/bloodadvances.2018019976","volume":"2","author":"S Sengsayadeth","year":"2018","unstructured":"Sengsayadeth S, Gatwood KS, Boumendil A, Labopin M, Finke J, Ganser A, et al. Conditioning intensity in secondary AML with prior myelodysplastic syndrome\/myeloproliferative disorders: an EBMT ALWP study. Blood Adv. 2018;2:2127\u201335.","journal-title":"Blood Adv"},{"key":"582_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/ajh.25087","volume":"93","author":"Z Li","year":"2018","unstructured":"Li Z, Labopin M, Ciceri F, Blaise D, Tischer J, Ehninger G, et al. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. Am J Hematol. 2018;93:769\u201377.","journal-title":"Am J Hematol"},{"key":"582_CR15","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"582_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610\u20131.","journal-title":"Bone Marrow Transplant"},{"key":"582_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295\u2013304.","journal-title":"Transplantation"},{"key":"582_CR18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"key":"582_CR19","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1405584","volume":"371","author":"JE Wagner","year":"2014","unstructured":"Wagner JE, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. New Engl J Med. 2014;371:1685\u201394.","journal-title":"New Engl J Med"},{"key":"582_CR20","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.bbmt.2014.05.015","volume":"20","author":"M Eapen","year":"2014","unstructured":"Eapen M, O\u2019Donnell P, Brunstein CG, Wu J, Barowski K, Mendizabal A, et al. Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2014;20:1485\u201392.","journal-title":"Biol Blood Marrow Transplant"},{"key":"582_CR21","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S1470-2045(11)70260-1","volume":"12","author":"M Eapen","year":"2011","unstructured":"Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011;12:1214\u201321.","journal-title":"Lancet Oncol"},{"key":"582_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1182\/blood-2013-05-506253","volume":"123","author":"M Eapen","year":"2014","unstructured":"Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123:133\u201340.","journal-title":"Blood"},{"key":"582_CR23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1182\/blood-2014-09-599241","volume":"126","author":"L Pascal","year":"2015","unstructured":"Pascal L, Tucunduva L, Ruggeri A, Blaise D, Ceballos P, Chevallier P, et al. Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. Blood. 2015;126:1027\u201332.","journal-title":"Blood"},{"key":"582_CR24","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-07-730564","volume":"128","author":"A Mancusi","year":"2016","unstructured":"Mancusi A, Ruggeri L, Velardi A. Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation. Blood. 2016;128:2616\u201323.","journal-title":"Blood"},{"key":"582_CR25","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","volume":"18","author":"SO Ciurea","year":"2012","unstructured":"Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1835\u201344.","journal-title":"Biol Blood Marrow Transplant"},{"key":"582_CR26","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3324\/haematol.2012.077685","volume":"98","author":"A Ruggeri","year":"2013","unstructured":"Ruggeri A, Rocha V, Masson E, Labopin M, Cunha R, Absi L, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Soci\u00e9t\u00e9 Francophone d\u2019Histocompatibilit\u00e9 et d\u2019Immunog\u00e9n\u00e9tique (SFHI) and Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC) analysis. Haematologica. 2013;98:1154\u201360.","journal-title":"Haematologica"},{"key":"582_CR27","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","volume":"53","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of Donor-specific Anti-HLA Antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53:521\u201334.","journal-title":"Bone Marrow Transplant"},{"key":"582_CR28","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.bbmt.2018.04.008","volume":"24","author":"S Sengsayadeth","year":"2018","unstructured":"Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, et al. Transplant outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biol Blood Marrow Transplant. 2018;24:1406\u201314.","journal-title":"Biol Blood Marrow Transplant"},{"key":"582_CR29","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He W, Cahn J-Y, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730\u20138.","journal-title":"J Clin Oncol"},{"key":"582_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","volume":"11","author":"A Ruggeri","year":"2018","unstructured":"Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018;11:40.","journal-title":"J Hematol Oncol"},{"key":"582_CR31","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.bbmt.2018.01.005","volume":"24","author":"R Dul\u00e9ry","year":"2018","unstructured":"Dul\u00e9ry R, M\u00e9nard A-L, Chantepie S, El-Cheikh J, Fran\u00e7ois S, Delage J, et al. Sequential conditioning with thiotepa in T cell-replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with matched related, haplo-mismatched, and unrelated donors. Biol Blood Marrow Transplant. 2018;24:1013\u201321.","journal-title":"Biol Blood Marrow Transplant"},{"key":"582_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","volume":"118","author":"CG Brunstein","year":"2011","unstructured":"Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282\u20138.","journal-title":"Blood"},{"key":"582_CR33","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/leu.2015.98","volume":"29","author":"A Ruggeri","year":"2015","unstructured":"Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29:1891\u2013900.","journal-title":"Leukemia"},{"key":"582_CR34","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/bmt.2014.109","volume":"49","author":"X-D Mo","year":"2014","unstructured":"Mo X-D, Zhao X-Y, Liu D-H, Chen Y-H, Xu L-P, Zhang X-H, et al. Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances. Bone Marrow Transplant. 2014;49:1070\u20135.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0582-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:54Z","timestamp":1684617294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0582-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0582-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]},"assertion":[{"value":"4 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Frederic Baron has received travel grants from Celgene, Abbvie, Novartis and Sanofi. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}